STOMP: Study of Tecovirimat for Human Monkeypox Virus

Study at a Glance

Estimated Time Commitment

8 weeks; Study medication for 14 days; Daily self-assessment

Eligibility

Laboratory or presumptive Human MonkeyPox infection; Illness <14 days from study entry with at least one active (non-scabbed) lesion

Diagnosis Required

None—if enrolled as presumed, and swabs come back negative, will stop study drug and be followed for safety

Diseases Being Studied

Human Monkey Pox infection
Location: Robert B. Green Clinic and Clinical Research Unit at MARC

Clinicaltrials.gov identifier: NCT05534984

Meet Your Clinical Research Team